Patrick R. Harrington

Patrick R. Harrington

Auto-generated profile, based on publicly available information

Patrick R. Harrington

Division of Antivirals, Office of Infectious Diseases, Center for Drug Evaluation and Research, Food and Drug Administration , Silver Spring, Maryland

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2011 in Hepatology
Verified
Journal Article
Open access
PDF file
PHPatrick R. Harrington
Patrick R. Harrington
WZWen Zeng
Wen Zeng
LNLisa K. Naeger
Lisa K. Naeger
Boceprevir- and telaprevir-based treatments for chronic hepatitis C virus (HCV) infection use specific response-guided therapy (RGT) guidelines. Eligibility for shortened treatment duration is based on achieving undetectable HCV RNA early during treatment. It is unclear whether a detected HCV RNA level that is below the assay lower limit of quantitation (detectable/BLOQ) is comparable to an undetectable HCV RNA level for RGT decision making. We analyzed data from boceprevir and telaprevir clinical trials to obtain a comprehensive understanding of the frequency and clinical relevance of detectable/BLOQ HCV RNA measurements. In Phase 3 trials P05216 (boceprevir), C216 (telaprevir), and 108 (telaprevir), detectable/BLOQ levels were reported for approximately 10%-20% of all on-treatment HCV RNA measurements. In P05216 and C216, subjects with detectable/BLOQ HCV RNA, on average, had a reduced sustained virologic response (SVR) rate compared with subjects with undetectable HCV RNA at the same on-treatment timepoint. At key RGT timepoints (week 8 for boceprevir, week 4 for telaprevir), subjects with detectable/BLOQ HCV RNA had an approximately 20% lower SVR rate compared with subjects with undetectable HCV RNA, and this difference widened for later on-treatment timepoints. A similar trend was observed for Study 108, but the differences in SVR rates were modest, potentially explained by a higher frequency of reported detectable/BLOQ results. Analyses of Phase 2 boceprevir and telaprevir trials indicated subjects with detectable/BLOQ HCV RNA at RGT timepoints benefited from extended treatment duration. Conclusion: During boceprevir- and telaprevir-based treatment, subjects with detectable/BLOQ HCV RNA had a reduced virologic response compared with subjects with undetectable HCV RNA. Eligibility for shortened treatment duration should be based on achieving undetectable HCV RNA (i.e., HCV RNA not detected) at RGT decision timepoints. (Hepatology 2012)

1 February 2017 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
TKTakashi E. Komatsu
Takashi E. Komatsu
SBSarita Boyd
Sarita Boyd
ASAdam Sherwat
Adam Sherwat
LTLaRee Tracy
LaRee Tracy
LNLisa K. Naeger
Lisa K. Naeger
PHPatrick R. Harrington
Patrick R. Harrington

1 December 2017 in Hepatology
Verified
Journal Article
Closed access
PDF file
PHPatrick R. Harrington
Patrick R. Harrington
TKTakashi E. Komatsu
Takashi E. Komatsu
DDDamon J. Deming
Damon J. Deming
EDEric F. Donaldson
Eric F. Donaldson
JOJulian J. O'REar
Julian J. O'REar
LNLisa K. Naeger
Lisa K. Naeger

22 December 2023 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
PHPatrick R. Harrington
Patrick R. Harrington
JCJie Cong
Jie Cong
STStephanie B. Troy
Stephanie B. Troy
JRJonathan M.O. Rawson
Jonathan M.O. Rawson
JOJulian J. O’rear
Julian J. O’rear
DBDebra Birnkrant
Debra Birnkrant
This report describes data from two randomized, double-blind clinical trials that investigated COVID-19 rebound following treatment with or without nirmatrelvir/ritonavir.

22 May 2015 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
PHPatrick R. Harrington
Patrick R. Harrington
DDDamon J. Deming
Damon J. Deming
TKTakashi E. Komatsu
Takashi E. Komatsu
LNLisa K. Naeger
Lisa K. Naeger
To the Editor—We read with interest the unexpected findings by Sidharthan et al that indicate that detected or quantifiable hepatitis C virus (HCV) RNA at the end of direct-acting antiviral (DAA) treatment does not preclude sustained virologic response (SVR)12 [1]. Using the Abbott HCV real-time assay (lower limit of quantitation [LLOQ], 12 IU/mL), the authors reported that among patients treated with sofosbuvir + ledipasvir ± GS-9669 or GS-9451 for 6 or 12 weeks, HCV RNA was detected (

28 May 2015 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
PHPatrick R. Harrington
Patrick R. Harrington
RFRussell Fleischer
Russell Fleischer
SCSarah M. Connelly
Sarah M. Connelly
LLLinda L. Lewis
Linda L. Lewis
JMJeffrey Murray
Jeffrey Murray
In clinical trials of interferon-free, direct-acting antiviral treatment of chronic hepatitis C, subjects who received ribavirin had reduced lymphocyte levels (median decline of approximately 0.4–0.5 × 109 cells/L). A modest decline in CD4+ T cells was observed in subjects with human immunodeficiency virus type 1 coinfection without documented opportunistic infections.